Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea

Study Identifier
229666-007
CT.gov Identifier
NCT02555761
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Conjunctivitis
    • Study Drug
  • Alcaftadine Ophthalmic Solution 0.25%
    • Phase
    N/A
    Sex
    Female & Male
    Age
    2+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    -Patients with itching associated with allergic conjunctivitis.
    Exclusion Criteria:
    -Patients with hypersensitivity to Lastacaft® or its components.

    Protocol Summary

    This post-marketing surveillance study will assess the safety and efficacy of Lastacaft® Opthalmic Solution 0.25% (Alcaftadine) for the prevention of itching associated with Allergic Conjunctivitis as prescribed as standard of care in clinical practice in Korea.

    Study Locations

    Location
    Status
    Location
    Seo-myeon St.Mary's Hospital
    Busan, Republic of Korea, 47254
    Status
    Not applicable
    Location
    SeoMyeon St. Eye Clinic
    Busan, Republic of Korea, 47254
    Status
    Not applicable
    Location
    Inje University Busan Paik Hospital
    Busan, Republic of Korea, 47395
    Status
    Not applicable
    Location
    Soojung Eye Hospital
    Busan, Republic of Korea, 48064
    Status
    Not applicable
    Location
    Inje University Haeundae Paik Hospital
    Busan, Republic of Korea, 48108
    Status
    Not applicable
    Location
    Saint Mary Bright Eye Clinic
    Busan, Republic of Korea, 48415
    Status
    Not applicable
    Showing {first} - {last} of {total} Results